NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased securities of Akero Therapeutics, Inc. ("Akero" or the "Company") (NASDAQ:AKRO) between September 13, 2022 and October 9, 2023, inclusive (the "Class Period").
The Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) approximately 20% of the patients enrolled in the SYMMETRY study had cryptogenic cirrhosis and did not have definitive NASH at baseline; (2) the cryptogenic cirrhotic patients included in the SYMMETRY study did not have biopsy-proven compensated cirrhosis ...
AKRO)>Full story available on Benzinga.com